DGAP-News

STRATEC remains on track in first quarter of 2015

DGAP-News: STRATEC Biomedical AG / Key word(s): Quarter
Results/Interim Report
STRATEC remains on track in first quarter of 2015

29.04.2015 / 07:32

---------------------------------------------------------------------

STRATEC remains on track in first quarter of 2015

- Sales of EUR 34.5 million in 3M/2015 (+0.5%; 3M/2014: EUR 34.4 million)
- EBIT of EUR 5.8 million in 3M/2015 (+9.7%; 3M/2014: EUR 5.3 million*)
- EBIT margin of 16.9% in 3M/2015 (+140 basis points; 3M/2014: 15.5%*)
- Earnings per share of EUR 0.40 in 3M/2015 (+8.1%; 3M/2014: EUR 0.37*)
- Ongoing strong cash flow performance /
free cash flow up 17.3% on previous year
- Major middleware software contract concluded
- Proposed dividend of EUR 0.70 per share for 2014
(distribution in previous year: EUR 0.60)

Birkenfeld, April 29, 2015

STRATEC Biomedical AG, Birkenfeld, Germany (Frankfurt: SBS; Prime Standard,
TecDAX) today announced its results for the period from January 1, 2015 to
March 31, 2015 upon the publication of its Interim Report as of March 31,
2015.

Key figures (EUR 000s)     01.01.- 03.31.2015  01.01.- 03.31.2014    Change
Sales                                  34,547              34,370     +0.5%
EBIT                                    5,840              5,326*     +9.7%
EBIT margin (%)                          16.9               15.5*  +140 bps
Consolidated net income                 4,739              4,372*     +8.4%
Earnings per share (EUR)                 0.40               0.37*     +8.1%

bps = basis points

* 2014 figure adjusted to exclude a one-off negative item resulting from
the recognition in the first quarter of expenses for the remaining years of
the term of a management board contract for a retired member of the Board
of Management. Unadjusted results for the first quarter 2014 EBIT amounted
to EUR 4.4 million; the corresponding EBIT margin amounted to 12.7%,
consolidated net income to EUR 3.7 million and earnings per share to EUR
0.31. The actual amount of the aforementioned expense item may differ at
the time of payment from the amounts presented here.


Financial performance
First-quarter sales increased year-on-year by 0.5% to EUR 34.5 million.
Profitability improved significantly compared with the previous year. The
EBIT margin rose to 16.9%, up from 15.5% in the previous year (unadjusted